Therapeutic target for musculoskeletal inflammation
US11655506B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jan 14, 2015 |
| Grant date | May 23, 2023 |
| Priority date | — |
| Expiry date | Feb 19, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for monitoring a treatment of a subject having a musculoskeletal disorder is provided. The method includes measuring a first expression level of at least two biomarkers at a treatment site prior to the treatment and measuring a second expression level of the at least two biomarkers at the treatment site after the treatment begins. The method further includes comparing the first expression level of the at least two biomarkers prior to the treatment to the second expression level of the at least two biomarkers post treatment and continuing the treatment, altering the treatment or stopping the treatment based on the comparison. A method of treating a musculoskeletal disorder in a subject is also provided. The method includes removing a aggrecan-hyaluronan matrix from a treatment site in the subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.